Want to see HK:6681 full AI Analyst Report?
6681 Stock Chart & Stats
HK$5.70
--
Market closed
HK$5.70
--
Day’s Range― - ―
52-Week RangeHK$0.61 - HK$8.48
Previous CloseN/A
VolumeN/A
Average Volume (3M)54.99M
Market Cap
HK$1.19B
Enterprise ValueHK$1.83B
Total Cash (Recent Filing)HK$658.44M
Total Debt (Recent Filing)HK$556.24M
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Mar 26, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding1,358,278,000
10 Day Avg. Volume149,611,819
30 Day Avg. Volume54,986,584
Financial Highlights & Ratios
PEG Ratio-0.94
Price to Book (P/B)69.27
Price to Sales (P/S)30.65
P/FCF Ratio-32.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)HK$471.47M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthTwo consecutive years of very strong revenue growth indicate expanding commercial traction for the company’s neurological healthcare products and solutions. If sustained, this scaling can improve operating leverage, broaden market reach, and provide a larger base for future profitability.
Healthy Gross MarginA gross margin of roughly 41% suggests the company retains meaningful value after direct costs and may have room to support product development, commercialization, and operating investment. Maintaining this margin as revenue grows would strengthen the potential path toward breakeven.
Improving Equity PositionThe return to positive equity represents a meaningful improvement from prior-year deficits and indicates some strengthening of the capital base. Combined with narrowing losses over time, this provides evidence of progress, although the company still faces substantial financial pressure.
Bears Say
Persistent Deep LossesThe company remains far from breakeven despite rapid revenue growth, because operating costs are still well above the current revenue base. Persistent negative EBIT, EBITDA, and net income limit internally generated capital and make profitable scaling a central execution requirement.
Negative Cash GenerationContinued operating and free cash outflows show that the business is not yet funding itself through operations. Ongoing cash burn can constrain investment flexibility and increase dependence on external financing, especially while the company is still reporting substantial losses.
High And Rising LeverageDebt growth alongside a highly elevated debt-to-equity ratio leaves the capital structure financially stressed relative to the company’s operating scale. High leverage can restrict future capital allocation and increase the consequences of continued losses and negative cash flow.
BrainAurora Medical Technology Limited News
6681 FAQ
What was BrainAurora Medical Technology Limited’s price range in the past 12 months?
BrainAurora Medical Technology Limited lowest stock price was HK$0.60 and its highest was HK$8.48 in the past 12 months.
What is BrainAurora Medical Technology Limited’s market cap?
BrainAurora Medical Technology Limited’s market cap is HK$1.19B.
When is BrainAurora Medical Technology Limited’s upcoming earnings report date?
BrainAurora Medical Technology Limited’s upcoming earnings report date is Mar 26, 2027 which is in 151 days.
How were BrainAurora Medical Technology Limited’s earnings last quarter?
BrainAurora Medical Technology Limited released its earnings results on Aug 28, 2026. The company reported -HK$0.117 earnings per share for the quarter.
Is BrainAurora Medical Technology Limited overvalued?
According to Wall Street analysts BrainAurora Medical Technology Limited’s price is currently Overvalued.
Does BrainAurora Medical Technology Limited pay dividends?
BrainAurora Medical Technology Limited does not currently pay dividends.
What is BrainAurora Medical Technology Limited’s EPS estimate?
BrainAurora Medical Technology Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BrainAurora Medical Technology Limited have?
BrainAurora Medical Technology Limited has 1,358,278,000 shares outstanding.
What happened to BrainAurora Medical Technology Limited’s price movement after its last earnings report?
BrainAurora Medical Technology Limited reported an EPS of -HK$0.117 in its last earnings report. Following the earnings report the stock price went down -1.954%.
Which hedge fund is a major shareholder of BrainAurora Medical Technology Limited?
Currently, no hedge funds are holding shares in HK:6681
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BrainAurora Medical Technology Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-88.51%
12-Months-Change
Fundamentals
Return on Equity
-124.83%
Trailing 12-Months
Asset Growth
52.83%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
BrainAurora Medical Technology Limited
BrainAurora Medical Technology Limited provides system integral software solutions for hospitals and research projects in Mainland China. The company develops medical-grade digital therapy (DTx) products for cognitive impairment. It offers the evaluation and intervention of cognitive impairments to treat vascular diseases, neurodegenerative diseases, psychological disorders, and child development deficiencies. The company develops the Brain Function Information Management Platform software system, an evidence-based, medical-grade DTx product; Basic Cognitive Testing Software, an assessment of patients for basic cognitive capacity; Cognitive Ability Supplemental screening and assessment software, a solution designed to facilitate healthcare professionals assessment of patients; and Dyslexia Supplemental Screening and Assessment Software, a solution designed to facilitate the assessment of risk of developmental dyslexia in children. It also develops covid-19 induced cognitive impairment assessment and recovery training software; ADHD assessment and treatment software; quantitative cognitive assessment software for depression; depression treatment software; and cognitive impairment assessment software and cognitive impairment treatment software solutions. In addition, the company provides marketing services. BrainAurora Medical Technology Limited was founded in 2012 and is headquartered in Shaoxing, China.
Technical Analysis
Hangzhou Tigermed Consulting Co., Ltd. Class H
―
Ocumension Therapeutics
―
Frontage Holdings Corp.
―
Lepu Biopharma Co. Ltd. Class H
―
Zhaoke Ophthalmology Ltd.
―